Login
$SCTX
$15.59 +$0.22 (1.43%) After hours

$SCTX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400

02 Sep 2026 10-Q
02 Sep 2026 8-K: Results of Operations and Financial Condition

Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent gene...

03 Aug 2026 SCHEDULE 13G
30 Jul 2026 SCHEDULE 13D
30 Jul 2026 SCHEDULE 13D
29 Jul 2026 Form 4: Orbimed Advisors Llc, Director and 1 other

Received 348,825 shares by conversion · Bought 1,000,000 shares ($15M)

29 Jul 2026 SCHEDULE 13D
29 Jul 2026 Form 4: Gordon Carl L, Director

Received 348,825 shares by conversion · Bought 1,000,000 shares ($15M)

29 Jul 2026 Form 4: Ah Bio Fund II, L.p., 10% owner and 5 others

Received 2,749,392 shares by conversion · Bought 333,333 shares ($5M)

29 Jul 2026 Form 4: Doudna Jennifer A, 10% owner

Received 12,511 shares by conversion

28 Jul 2026 Form 4: Aghazadeh Behzad, Director and 2 others

Bought 2,383,333 shares ($36.1M) · Bought 7,905 shares ($144K)

28 Jul 2026 Form 4: Staahl Brett, 10% owner

Granted 4,755 Stock Option (Right to Buy) · Granted 19,385 Stock Option (Right to Buy) · Granted 19,385 Performance-based Stock Option (Right to Buy)

27 Jul 2026 Form 4: Lucas Svetlana, Chief Business Officer

Granted 9,547 Stock Option (Right to Buy) · Bought 3,000 shares ($45K) · Granted 109,426 Stock Option (Right to Buy) · 1 more

27 Jul 2026 Form 4: Oakes Benjamin L., Director

Granted 12,969 Stock Option (Right to Buy) · Granted 264,784 Stock Option (Right to Buy) · Granted 429,599 Performance-based Stock Option (Right to Buy)

27 Jul 2026 Form 4: Gordon Carl L, Director

Granted 14,725 Stock Option (Right to Buy)

27 Jul 2026 Form 4: Watson James Dean, Director

Granted 14,725 Stock Option (Right to Buy)

27 Jul 2026 Form 4: Bleharski Joshua, Director

Granted 14,725 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support